Risk of Strongyloides Hyperinfection Syndrome when prescribing dexamethasone in severe COVID-19

Strongyloides stercoralis, a parasitic nematode infection endemic in tropical and subtropical regions, is estimated to infect 30 to 100 million people worldwide. Patients deemed at high risk (migrants with high risk exposure) may need empirical treatment with ivermectin, which has an efficacy of 85% as a single dose [5]. COVID-19 patients with undiagnosed Strongyloides infection undergoing immunosuppression are at risk of developing SHS.Funding source PLC is supported by the UCL Hospitals Comprehensive Biomedical Research Centre.CRediT author contribution statement Conceptualisation: A de W. Writing-review and editing by all authors.Declaration of competing interest The authors have no competing interests to declare.